Key facts
- · Type: New offering first sale 2026-04-15 · Amount sold: $4.81M · Total offering: $4.81M · SEC filing
- · Type: Amendment first sale 2019-06-25 · Amount sold: $10.88M · Total offering: $17.32M · SEC filing
- · Type: Amendment first sale 2019-06-25 · Amount sold: $7.20M · Total offering: $11.25M · SEC filing
- · Type: Amendment first sale 2019-06-25 · Amount sold: $6.03M · Total offering: $7.50M · SEC filing
- · Type: Amendment first sale 2019-06-25 · Amount sold: $3.20M · Total offering: $7.50M · SEC filing
Newton, MASSACHUSETTS
Pharmaceuticals
6
$4.81M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-04-23 | New offering first sale 2026-04-15 | $4.81M | $4.81M | details · SEC filing |
| 2025-07-02 | Amendment first sale 2019-06-25 | $10.88M | $17.32M | SEC filing |
| 2024-07-02 | Amendment first sale 2019-06-25 | $7.20M | $11.25M | SEC filing |
| 2023-12-21 | Amendment first sale 2019-06-25 | $6.03M | $7.50M | SEC filing |
| 2022-12-22 | Amendment first sale 2019-06-25 | $3.20M | $7.50M | SEC filing |
| 2022-11-10 | Amendment first sale 2019-06-25 | $3.20M | $3.75M | SEC filing |
Want the whole picture on General Oncology, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on General Oncology, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on General Oncology, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from General Oncology, Inc.'s own filings with the SEC. The people those filings name are on the team page.